Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$125.79 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
433.68 million
Earnings per share
-0.060
Dividend per share
N/A
Year To Date Return
-13.24%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Latest News
Share Market News
Why this ASX healthcare share has risen over 200% in the past year
Share Gainers
Why these All Ords shares have doubled in value in 12 months
Healthcare Shares
Why Paradigm Biopharmaceuticals is one to watch in 2020
Share Market News
These 3 ASX healthcare shares could make you rich
Share Fallers
Paradigm share price tumbles lower on FDA update
Share Market News
Paradigm Biopharmaceuticals shares lower despite US update
Share Market News
Leading brokers name 3 ASX shares to sell today
Share Market News
Paradigm Biopharmaceuticals shares have skyrocketed. Should you invest?
Share Market News
Why this growing ASX healthcare company should be on everyone's watch lists
52-Week Highs
Why these ASX shares just raced to 52-week highs or better
Growth Shares
I would buy Zip Co and these ASX mid cap stars in February
How to invest
Are these the millionaire maker ASX shares of the 2020s?
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
PAR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Feb 2026 | $0.29 | $0.00 | 0.00% | 698,316 | $0.30 | $0.30 | $0.29 |
| 18 Feb 2026 | $0.29 | $-0.01 | -3.39% | 1,489,942 | $0.29 | $0.30 | $0.29 |
| 17 Feb 2026 | $0.30 | $-0.01 | -3.28% | 1,084,950 | $0.31 | $0.31 | $0.30 |
| 16 Feb 2026 | $0.31 | $0.01 | 3.33% | 593,155 | $0.30 | $0.31 | $0.30 |
| 13 Feb 2026 | $0.30 | $-0.01 | -3.28% | 505,628 | $0.31 | $0.31 | $0.30 |
| 12 Feb 2026 | $0.31 | $-0.01 | -3.23% | 736,127 | $0.31 | $0.31 | $0.31 |
| 11 Feb 2026 | $0.31 | $0.00 | 0.00% | 1,455,557 | $0.32 | $0.32 | $0.30 |
| 10 Feb 2026 | $0.31 | $-0.01 | -3.17% | 909,260 | $0.32 | $0.32 | $0.31 |
| 09 Feb 2026 | $0.32 | $0.03 | 10.34% | 1,242,668 | $0.31 | $0.32 | $0.30 |
| 06 Feb 2026 | $0.29 | $-0.02 | -6.56% | 901,677 | $0.31 | $0.31 | $0.29 |
| 05 Feb 2026 | $0.31 | $0.01 | 3.33% | 1,121,640 | $0.31 | $0.32 | $0.31 |
| 04 Feb 2026 | $0.30 | $-0.02 | -6.35% | 692,644 | $0.31 | $0.31 | $0.30 |
| 03 Feb 2026 | $0.32 | $0.02 | 6.78% | 1,377,251 | $0.30 | $0.32 | $0.29 |
| 02 Feb 2026 | $0.30 | $-0.01 | -3.28% | 1,742,989 | $0.31 | $0.31 | $0.30 |
| 30 Jan 2026 | $0.31 | $-0.01 | -3.17% | 1,010,740 | $0.32 | $0.32 | $0.31 |
| 29 Jan 2026 | $0.32 | $-0.02 | -6.06% | 890,629 | $0.33 | $0.33 | $0.32 |
| 28 Jan 2026 | $0.33 | $0.01 | 3.13% | 3,053,549 | $0.32 | $0.36 | $0.31 |
| 27 Jan 2026 | $0.32 | $-0.01 | -3.08% | 598,159 | $0.33 | $0.33 | $0.32 |
| 23 Jan 2026 | $0.33 | $0.00 | 0.00% | 729,748 | $0.32 | $0.34 | $0.32 |
| 22 Jan 2026 | $0.33 | $0.01 | 3.13% | 763,221 | $0.32 | $0.33 | $0.32 |
| 21 Jan 2026 | $0.32 | $-0.01 | -3.08% | 807,661 | $0.32 | $0.33 | $0.32 |
| 20 Jan 2026 | $0.33 | $-0.01 | -2.99% | 612,783 | $0.34 | $0.34 | $0.32 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 03 Feb 2026 | Paul Rennie | Exercise | 153,265 | $48,278 |
Exercise of options.
|
| 03 Feb 2026 | Paul Rennie | Buy | 153,265 | $99,622 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Rennie | Executive DirectorManaging DirectorExecutive Chairman | May 2014 |
Mr Rennie has sales, marketing, business development, operational and IP commercialization experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their director of business development. Paul also led the commercialization of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in several positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul is the founder of Paradigm Biopharmaceuticals.
|
| Mr Amos Meltzer | Non-Executive Director | Dec 2020 |
Mr Meltzer has over 30 years of experience in international trade and in commercializing technologies, principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialization of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously Amos served as General Counsel and IP director at two Nasdaq-listed companies Compugen and Gilat, as a non-executive director of a biotechnology company Evogene and as VP of Business Development. Amos currently serves as Chief Legal Officer of neuro-medical device company Synchron, Inc., chairman of the Board of Maverick LifeSciences.
|
| Mr Matthew James Fry | Non-Executive Director | Mar 2024 |
Mr Fry has more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of medical diagnostic products. Matthew has experience with global regulatory agencies, in particular the Australian TGA and US FDA.
|
| Ms Abby Macnish | Interim Company Secretary | Aug 2022 |
-
|
| Abby Macnish | Interim Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 20,216,245 | 5.09% |
| HSBC Custody Nominees (Australia) Limited | 14,090,211 | 3.55% |
| Kzee Pty Ltd <Kzee Superannuation Fund A/C> | 11,380,902 | 2.86% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 9,768,128 | 2.46% |
| Mr Paul John Rennie | 8,745,848 | 2.20% |
| BNP Paribas Nominees Pty Ltd <IB Au Noms Retailclient> | 8,535,566 | 2.15% |
| Mr Anthony Mark Van Der Steeg | 4,649,524 | 1.17% |
| Mr Adam William Huts | 3,680,000 | 0.93% |
| Nancy Edith Wilson Ghosh <Ghosh Family A/C> | 3,475,835 | 0.87% |
| BNP Paribas Noms Pty Ltd | 2,874,158 | 0.72% |
| Flinders Medical Centre Foundation | 2,620,000 | 0.66% |
| 39Kp Pty Ltd <Ross Family A/C> | 2,527,367 | 0.64% |
| Mrs Shay Elizabeth Lewis Thorp | 2,500,000 | 0.63% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 2,201,776 | 0.55% |
| Obsidian Global Gp Llc | 2,031,235 | 0.51% |
| J P Morgan Nominees Australia Pty Limited | 2,005,079 | 0.50% |
| Ms Yanicke Forfang | 1,950,000 | 0.49% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,838,801 | 0.46% |
| Hot Springs Superannuation Pty Limited <Hot Springs Limited S/F A/C> | 1,752,090 | 0.44% |
| Mr Ignatius John Misquitta & Mrs Margaret Misquitta | 1,650,000 | 0.42% |
